首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   207071篇
  免费   5194篇
  国内免费   1620篇
耳鼻咽喉   2847篇
儿科学   7520篇
妇产科学   6048篇
基础医学   26655篇
口腔科学   6041篇
临床医学   17087篇
内科学   36782篇
皮肤病学   4584篇
神经病学   12231篇
特种医学   11154篇
外国民族医学   108篇
外科学   30471篇
综合类   3426篇
现状与发展   3篇
一般理论   4篇
预防医学   16978篇
眼科学   4614篇
药学   14839篇
  13篇
中国医学   944篇
肿瘤学   11536篇
  2021年   924篇
  2018年   3997篇
  2017年   4265篇
  2016年   3556篇
  2015年   5457篇
  2014年   5034篇
  2013年   3957篇
  2012年   10712篇
  2011年   5702篇
  2010年   2766篇
  2009年   4393篇
  2008年   2670篇
  2007年   3366篇
  2006年   3603篇
  2005年   11753篇
  2004年   12975篇
  2003年   8574篇
  2002年   3758篇
  2001年   4632篇
  2000年   2050篇
  1999年   6235篇
  1998年   764篇
  1992年   6981篇
  1991年   7172篇
  1990年   7414篇
  1989年   7011篇
  1988年   6522篇
  1987年   6296篇
  1986年   5993篇
  1985年   5287篇
  1984年   3611篇
  1983年   2923篇
  1982年   1004篇
  1981年   775篇
  1980年   841篇
  1979年   3836篇
  1978年   2364篇
  1977年   1784篇
  1976年   1559篇
  1975年   2474篇
  1974年   3106篇
  1973年   2741篇
  1972年   2757篇
  1971年   2744篇
  1970年   2556篇
  1969年   2466篇
  1968年   2241篇
  1967年   2164篇
  1966年   1898篇
  1965年   1132篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Cao  Jie  Xie  Chengyu  Hou  Zhiru 《Ecotoxicology (London, England)》2022,31(2):259-270
Ecotoxicology - Soil heavy metal pollution evaluations are a necessary measure for mine ecological control projects. In this study, the heavy metals Pb, Zn and Cd were studied in mining areas,...  相似文献   
2.
本文通过对《中医基本名词术语中英对照国际标准》和《WHO西太平洋地区传统医学名词术语国际标准》舌诊术语进行比较,分析两部标准中舌诊术语英译的优缺点,提出更适宜优先选择作为中医舌诊术语英译标准的方案,以期为中医名词术语标准化工作提供参考。  相似文献   
3.
Clinical and Experimental Medicine - Colon cancer is one of most common cancers. The progression of various cancers is driven by miRNA-570. The role of miRNA-570 in the progression of colon cancer...  相似文献   
4.
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group".  相似文献   
5.
BackgroundComminuted patellar fractures are not rare, and the ideal treatment method remains controversial. The present study was conducted to evaluate effects and compare complications of two different methods used to treat comminuted patellar fractures.MethodsFrom March 2010 to August 2016, 102 cases of 34-C2 or 34-C3 comminuted patellar fractures were treated at our hospital, wherein patients received two different treatments: titanium cable tension band with cerclage method (group A) and intrafragmentary screws with X-shaped plating technique (group B). At follow-ups, articular step-off, range of motion (ROM), Lysholm scores, time of union, and complications were recorded and analyzed. Radiographic and clinical data as well as rate of complications were statistically analyzed.ResultsIn total, 87 patients were included in the final analysis (n = 47 in group A and n = 40 in group B). No significant differences were noted in terms of cost of implant, age, gender, rate of 34-C3 fractures, rate of layered inferior pole fractures, postoperative articular step-off and union time. At 2-year follow-up, average Lysholm scores, ROM and rate of complications were (89.0 ± 4.5), (122°±12°) and (27.7%) in group A and (90.2 ± 3.9), (124°±11°) and (17.5%) in group B, respectively, with no significant differences (p > 0.05). The mean time of surgery in group B was shorter than that in group A with significant difference (p < 0.05).ConclusionsTreatment using the intrafragmentary screws and plate method for amenable comminuted patellar fractures achieved similar complication rate and favorable functional outcomes at the 2-year follow-up, which was comparable to the titanium cable tension band with cerclage method. Thus, the intrafragmentary screws and plate method is effective, safe and convenient for 34-C2/C3 comminuted patellar fractures, especially appropriate for patients with layered fragments.  相似文献   
6.
7.
8.
目的:观察应力刺激结合温经活血汤治疗骨折延迟愈合的临床疗效。方法:40例随机分成两组各20例,两组均行应力刺激。治疗组给予温经活血汤治疗、对照组给予接骨七厘片治疗。结果:治疗4周、8周两组血清ALP、BGP指标比较差异有统计学意义(P<0.05),治疗4周、8周和治疗结束后4周骨痂评分两组比较差异均有统计学意义(P<0.05),总体疗效治疗组优于对照组(P<0.05)。结论:应力刺激结合温经活血汤治疗骨折延迟愈合疗效较好。  相似文献   
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号